Regeneron Pharmaceuticals

BioFuture 2026 Gathers 100+ Speakers to Tackle Biopharma AI, Funding, Policy

New York City – – September 29, 2026 -- Demy-Colton has released the agenda for BioFuture 2026, a two-day conference set for October 27–28 at Cure, 345 Park Avenue South, drawing more than 100 speakers and over 50 presenting companies from biopharma, investment, technology and policy sectors.

Conference agenda spans AI, oncology, biotech financing and global drug development

Speakers include representatives from Johnson & Johnson, Regeneron Pharmaceuticals, Schrödinger, Piper Sandler and Mizuho Securities. Sponsors backing the event include Regeneron Pharmaceuticals, Russo Partners, WuXi AppTec, Blue Matter, Cure, Evotec, Ipsen, Thermo Fisher Scientific, Big4Bio, HMA Consulting, Withum and Hogan Lovells Cadwalader.

PNH Drug Market to Reach $1.5B in 2025, Grow at 7.1% CAGR

Las Vegas – September 20, 2026 -- The paroxysmal nocturnal hemoglobinuria (PNH) market across the seven major markets was valued at approximately $1.5 billion in 2025 and is projected to grow at a compound annual growth rate of 7.1% through 2036, according to DelveInsight.

Regeneron's pozelimab-cemdisiran combination leads next wave of PNH therapies

Pozelimab, a fully human anti-C5 monoclonal antibody developed on Regeneron's VelocImmune platform, is expected to generate the highest revenue among emerging PNH therapies in the seven major markets. The drug is being tested in combination with Alnylam's siRNA therapy cemdisiran; Regeneron has said Phase III results in PNH are anticipated in the fourth quarter of 2026 or the first quarter of 2027.

Regeneron Sued Over Failed Melanoma Trial, $11B Market Cap Loss

San Francisco – September 11, 2026 -- Hagens Berman Sobol Shapiro LLP has filed a securities class action against Regeneron Pharmaceuticals (NASDAQ: REGN) after the failure of a Phase 3 melanoma trial wiped out $11 billion in market capitalization. The suit covers investors who purchased Regeneron shares between September 11, 2026, and September 11, 2026, with a lead plaintiff deadline set for September 11, 2026.

Regeneron's Fianlimab-Libtayo combination failed to hit its primary endpoint

The complaint centers on Regeneron's Phase 3 trial testing Fianlimab combined with Libtayo as a first-line treatment for metastatic or locally advanced melanoma, a therapy management repeatedly called a "potential blockbuster." On September 11, 2026, Regeneron disclosed the trial did not reach statistical significance on its primary endpoint of progression-free survival.